In particular, the PSMA gene, a valuable biomarker for predicting the outcome in patients with prostate cancer, was detected in CTCs of many metastatic prostate cancer patients (57.14% (8/14 patients) at CTC-μChip and 42.86% (6/14 patients) at AdnaTest) (Figure 6c). The gene discussed is FOLH1; the disease is prostate carcinoma.